Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth

Metastatic castration resistant prostate cancer (mCRPC) relapses due to acquired resistance to docetaxel-based chemotherapy and remains a major threat to patient survival. In this report, we tested the effectiveness of a dual CXCR4/E-selectin antagonist, GM-I1359, in vitro and in vivo, as a single a...

Descripción completa

Detalles Bibliográficos
Autores principales: Festuccia, Claudio, Mancini, Andrea, Gravina, Giovanni Luca, Colapietro, Alessandro, Vetuschi, Antonella, Pompili, Simona, Ventura, Luca, Delle Monache, Simona, Iorio, Roberto, Del Fattore, Andrea, Fogler, William, Magnani, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017374/
https://www.ncbi.nlm.nih.gov/pubmed/31877673
http://dx.doi.org/10.3390/cells9010032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017374/
https://www.ncbi.nlm.nih.gov/pubmed/31877673
http://dx.doi.org/10.3390/cells9010032

Ejemplares similares